Montecillo-Aguado et al., 2019 - Google Patents
Cross‐reaction, enhancement, and neutralization activity of dengue virus antibodies against zika virus: a study in the Mexican populationMontecillo-Aguado et al., 2019
View PDF- Document ID
- 11990864103703787909
- Author
- Montecillo-Aguado M
- Montes-Gómez A
- García-Cordero J
- Corzo-Gómez J
- Vivanco-Cid H
- Mellado-Sánchez G
- Muñoz-Medina J
- Gutiérrez-Castañeda B
- Santos-Argumedo L
- González-Bonilla C
- Cedillo-Barrón L
- Publication year
- Publication venue
- Journal of immunology research
External Links
Snippet
Zika virus (ZIKV), an emerging mosquito‐borne flavivirus, has quickly spread in many regions around the world where dengue virus (DENV) is endemic. This represents a major health concern, given the high homology between these two viruses, which can result in …
- 241000907316 Zika virus 0 title abstract description 121
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
- C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Montecillo-Aguado et al. | Cross‐reaction, enhancement, and neutralization activity of dengue virus antibodies against zika virus: a study in the Mexican population | |
| Boigard et al. | Zika virus-like particle (VLP) based vaccine | |
| Junjhon et al. | Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction | |
| Sukupolvi-Petty et al. | Type-and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes | |
| Kam et al. | Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections | |
| Lai et al. | Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II | |
| Priyamvada et al. | Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus | |
| Smith et al. | Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection | |
| Yu et al. | Delineating antibody recognition against Zika virus during natural infection | |
| Tsai et al. | Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies | |
| Malafa et al. | Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans | |
| Wang et al. | High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis | |
| Young et al. | An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients | |
| Vogt et al. | Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step | |
| Wan et al. | Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1 | |
| White et al. | An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection | |
| Tai et al. | Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses | |
| Lin et al. | The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry | |
| Bos et al. | Dengue: a growing threat requiring vaccine development for disease prevention | |
| Baldwin et al. | Purified inactivated Zika vaccine candidates afford protection against lethal challenge in mice | |
| Zlatkovic et al. | Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice | |
| Tsai et al. | Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy for dengue vaccine | |
| Aoki et al. | Cross-linking of rotavirus outer capsid protein VP7 by antibodies or disulfides inhibits viral entry | |
| Galula et al. | Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine | |
| Tsai et al. | Complexity of human antibody response to dengue virus: implication for vaccine development |